UNSPSC 51372041: Nalfurafine hydrochloride

This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25CC4N0P8J. European Medicines Agency schedules Nalfurafine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32294. Nalfurafine hydrochloride generally arises in the molecular formula C28H32N2O5.CLH. The term 'nalfurafine hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule nalfurafine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALFURAFINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nalfurafine hydrochloride bears US NLM identifiers UMLS ID C1610428 and NCI Concept Code C80586. SMILES: CN([C@@H]1CC[C@]2([C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3CC6CC6)O)O)C(=O)/C=C/C7CCOC7.CL.

UNSPSC 51372041 Nalfurafine hydrochloride is a Commodity code that, based on recent state and local procurement activity, does not align with actual buying patterns under this classification. The single recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—involves procurement of naloxone (an opioid antagonist used in overdose reversal), not nalfurafine hydrochloride (a kappa receptor agonist indicated for pruritus). The mismatch between the code's nominal pharmaceutical scope and the naloxone-focused opportunity suggests either a tagging error in the county's procurement system or limited genuine activity under this specific commodity code. State and local procurement records show minimal recent activity under this code tier.

Without additional opportunities in the source to establish issuing-body patterns or geographic concentration, no reliable characterization of buyer types, frequency, or regional distribution can be drawn. The single opportunity does not support conclusions about typical procurement patterns, renewal cycles, or competitive positioning under this code. Business development professionals should verify whether state and local procurement systems routinely use this code for nalfurafine transactions, confirm the intended pharmaceutical scope through direct conversations with state health and corrections agencies, and monitor cooperative purchasing vehicles that may consolidate opioid-related pharmaceutical procurement across multiple jurisdictions.